Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer

In a multicentre phase 1-2 dose-escalation and expansion study, 136 patients with previously treated advanced RAS-mutant non-small-cell lung cancer received the oral RAS inhibitor daraxonrasib at doses up to 300 mg once daily. Responses were seen in 31% of patients at doses up to 120 mg, 34% at 160-220 mg and 37% at 300 mg, while grade 3 or higher adverse events occurred in 54% and adverse events of any grade in 99%. This is an early-phase, single-arm study without a comparator and without mature survival data, so it establishes activity and a dose range rather than efficacy against current standards.